Overview of Ketamine Guidelines in Psychiatric Disorders
Hesham Maged Mohamed Abdelfatah, Mahmoud Mohamed Gomaa
International Journal of Psychiatry September 26, 2025 DOI: 10.33140/ijp.10.03.04 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Intravenous ketamine |
| Topics | Depression Ketamine Esketamine |
| Keywords | Depression economics Suicidal ideation Bipolar disorder Protocol science Fluoxetine Management of depression Drug |
| Key findings | Ketamine has demonstrated efficacy in improving major depression where conventional first-line treatments have not been fully effective. |
Abstract
Ketamine has anti depressive characters and approved by (FDA) for the induction and maintenance of anesthesia, Ketamine has been incorporated into the management of psychiatric disorders, such as Major Depressive Disorder (MDD) especially with suicidal ideation or attempting, and of label in management of Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD).Intravenous ketamine regimen is not a first-line management for psychiatric disorders and considered by the patient’s interdisciplinary team work after failure of standard treatment. Ketamine mechanism of action is different from existing treatments and has demonstrated efficacy in improving people with Major Depression Disorder where conventional first line management as antidepressants, psychotherapy, have not be fully effective. In this paper we discussed all aspects of ketamine Protocol and guidelines usages in psychiatric.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |